Dr. Orozco is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1100 Fairview Ave N, D3-190
Seattle, WA 98109
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2009 - 2012
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009- University of Washington School of MedicineClass of 2006
University of WashingtonPhD, Bioengineering, 1999 - 2004
Certifications & Licensure
CA State Medical License 2008 - Present
WA State Medical License 2009 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- Randomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2024-09-19 - At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation.Sofia H L Frost, Johnnie J Orozco, Tom A Bäck, Brian W Miller, Erlinda B Santos
Journal of Nuclear Medicine. 2024-09-03 - 1 citationsTargeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors.Johnnie J Orozco, Phuong T Vo, Ted A Gooley, Robyn L Haaf, Sally J Lundberg
Clinical Cancer Research. 2024-01-17
Journal Articles
- Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
Abstracts/Posters
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...Johnnie Orozco, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...Johnnie Orozco, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
$3.4 Million Grant to Find Safer, More Effective Leukemia TreatmentsJuly 27th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
